ATE218579T1 - Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen - Google Patents
Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogenInfo
- Publication number
- ATE218579T1 ATE218579T1 AT97941352T AT97941352T ATE218579T1 AT E218579 T1 ATE218579 T1 AT E218579T1 AT 97941352 T AT97941352 T AT 97941352T AT 97941352 T AT97941352 T AT 97941352T AT E218579 T1 ATE218579 T1 AT E218579T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- methods
- treating infections
- analogues
- indolicidin analogues
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- USSYUMHVHQSYNA-PYODXXEMSA-N (2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]-N-[(2R)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide Chemical class CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-PYODXXEMSA-N 0.000 title 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 abstract 1
- 108091005601 modified peptides Proteins 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2475496P | 1996-08-21 | 1996-08-21 | |
| US3494997P | 1997-01-13 | 1997-01-13 | |
| PCT/US1997/014779 WO1998007745A2 (en) | 1996-08-21 | 1997-08-21 | Compositions and methods for treating infections using analogues of indolicidin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE218579T1 true ATE218579T1 (de) | 2002-06-15 |
Family
ID=26698836
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01119148T ATE410441T1 (de) | 1996-08-21 | 1997-08-21 | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen |
| AT97941352T ATE218579T1 (de) | 1996-08-21 | 1997-08-21 | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01119148T ATE410441T1 (de) | 1996-08-21 | 1997-08-21 | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6180604B1 (de) |
| EP (1) | EP0925308B1 (de) |
| JP (2) | JP2001500477A (de) |
| AT (2) | ATE410441T1 (de) |
| CA (1) | CA2263799A1 (de) |
| DE (2) | DE69739035D1 (de) |
| ES (2) | ES2178000T3 (de) |
| HK (1) | HK1043475B (de) |
| WO (1) | WO1998007745A2 (de) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE20000918A1 (en) * | 1990-03-22 | 2001-05-30 | Sloan Kettering Inst Cancer | GP75 As a Tumor Vaccine for Melanoma |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| US6180604B1 (en) | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
| WO1999043357A1 (en) * | 1998-02-25 | 1999-09-02 | Micrologix Biotech Inc. | Indolicidin and cationic peptides conjugated with polymers |
| US6303575B1 (en) * | 1998-05-12 | 2001-10-16 | The Regents Of The University Of California | Indolicidin analogs and methods of using same |
| AU4253799A (en) * | 1998-06-12 | 2000-01-05 | Micrologix Biotech, Inc. | Cancer therapy with cationic peptides |
| US6444645B1 (en) * | 1998-06-18 | 2002-09-03 | The Regents Of The University Of California | Crosslink-stabilized indolicidin analogs |
| US6288212B1 (en) * | 1998-08-28 | 2001-09-11 | The University Of British Columbia | Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor |
| BR9914922A (pt) * | 1998-10-30 | 2001-07-10 | Interlink Biotechnologies Llc | Métodos para reduzir a extensão de degradação de protease de uma proteìna aplicada a ou produzida por uma planta, para inibir o crescimento de um patógeno vegetal e para produzir uma planta, peptìdeo, molécula de ácido nucleico, segmento de ácido nucleico, construção de ácido nucleico, planta transgênica, semente, célula vegetal, e, composição para o uso na proteção de um peptìdeo, polipeptìdeo ou proteìna da degradação da protease. |
| US6946261B1 (en) | 1998-11-20 | 2005-09-20 | Migenix Inc. | Efficient methods for producing anti-microbial cationic peptides in host cells |
| CA2364592A1 (en) * | 1999-03-03 | 2000-09-08 | Collin E. Thomas | Genetic and epigenetic manipulation of abc transporters and ecto-phosphatases for the conference of drug resistance and for the loss of drug resistance in biological systems and methods for the detection of ecto-phosphatase inhibitors |
| US7169889B1 (en) | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
| US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| US6576224B1 (en) | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| US6429211B1 (en) * | 2000-05-23 | 2002-08-06 | Bayer Corporation | Praziquantel compounds for treating diseases due to Sarcocystis Neospora Toxoplasma and Isospora |
| PL363153A1 (en) | 2000-06-16 | 2004-11-15 | Hercules Incorporated | Chemically-modified antimicrobial peptides, compositions and methods of production and use |
| JP2004533406A (ja) | 2000-10-18 | 2004-11-04 | フアーマセツト・リミテツド | ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド |
| US6660249B2 (en) | 2000-12-27 | 2003-12-09 | Salus Pharma, Inc. | Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections |
| US7214364B2 (en) | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| US6867183B2 (en) | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US7115572B2 (en) * | 2001-03-29 | 2006-10-03 | Council Of Scientific And Industrial Research | Indolicidin analogs with anti-microbial activity |
| US8658202B2 (en) | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
| US6759058B1 (en) * | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
| US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US20040235745A1 (en) * | 2001-06-22 | 2004-11-25 | Deber Charles M | Antimicrobial Peptides |
| US6835536B2 (en) * | 2001-08-21 | 2004-12-28 | Micrologix Biotech Inc. | Antimicrobial cationic peptides and formulations thereof |
| US6734165B2 (en) * | 2001-08-23 | 2004-05-11 | The Trustees Of Columbia University In The City Of New York | Method for re-sensitizing vancomycin resistant bacteria which selectively cleave a cell wall depsipeptide |
| JP4511173B2 (ja) * | 2001-08-24 | 2010-07-28 | マイジェニックス インコーポレイテッド | 抗菌性および抗炎症性ペプチド |
| US7312192B2 (en) | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| US7196059B2 (en) | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US6913903B2 (en) | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| US7166571B2 (en) | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| US20030219854A1 (en) * | 2002-03-21 | 2003-11-27 | Micrologix Biotech Inc. | Methods for producing modified anti-infective peptides |
| US7399583B2 (en) * | 2002-04-17 | 2008-07-15 | Novartis Ag | Method for the identification of inhibitors of the binding of ARE-containing mRNA and a HuR protein |
| ATE489462T1 (de) * | 2002-04-25 | 2010-12-15 | Toagosei Co Ltd | Antimikrobielles polypeptid und nutzung davon |
| US7345018B2 (en) | 2002-04-25 | 2008-03-18 | Reception Aps | Method of treating side effects induced by therapeutic agents |
| AU2003236521A1 (en) | 2002-06-13 | 2003-12-31 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
| IL150907A (en) * | 2002-07-25 | 2007-07-04 | Stephan Cherkez | Process for the preparation of stable amorphous calcium pseudomonate |
| SE0202613D0 (sv) * | 2002-09-04 | 2002-09-04 | Innate Pharmaceuticals Ab | Förfarande och prob för identifiering av ämnen som modifierar bakteriers virulens, som sådana identifierade ämnen samt deras användning |
| US7238669B2 (en) * | 2002-09-11 | 2007-07-03 | The Curators Of The University Of Missouri | Phage-display peptides as novel antimicrobial agents against Haemophilus influenzae |
| US20050245582A1 (en) * | 2002-09-12 | 2005-11-03 | The Hartz Mountain Corporation | High concentration topical insecticides containing pyrethroids |
| CA2502148A1 (en) * | 2002-10-16 | 2005-02-17 | Board Of Regents, The University Of Texas System | Methods and compositions for increasing the efficacy of biologically-active ingredients |
| BRPI0407374A (pt) | 2003-02-19 | 2006-01-10 | Univ Yale | Análogos de nucleosìdeo antiviral e métodos para tratar infecções virais, especialmente infecções de hiv |
| US20040260454A1 (en) * | 2003-06-11 | 2004-12-23 | Basir Otman A. | Vibro-acoustic engine diagnostic system |
| US7189403B2 (en) * | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
| US20050171063A1 (en) * | 2003-10-20 | 2005-08-04 | Pawan Malhotra | Use of phosphono derivatives as anti-malarials |
| ZA200603215B (en) * | 2003-10-22 | 2007-11-28 | Council Scient Ind Res | Use of selected amino acid-zinc complexes as antimalarial |
| WO2005049819A1 (ja) * | 2003-10-29 | 2005-06-02 | Toagosei Co., Ltd. | 抗菌ペプチド及びその利用 |
| US7994225B2 (en) * | 2004-03-17 | 2011-08-09 | Rempex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
| EP1732527A2 (de) * | 2004-03-17 | 2006-12-20 | Mpex Pharmaceuticals, Inc. | Verwendung und verabreichung von bakteriellen ausfluss-pumpenhemmern |
| US20050282755A1 (en) * | 2004-03-18 | 2005-12-22 | Ansata Therapeutics, Inc. | Compositions having antimicrobial activity and uses thereof |
| CN103223160B (zh) | 2004-07-19 | 2015-02-18 | 比奥孔有限公司 | 胰岛素-低聚物共轭物,制剂及其用途 |
| JP4507080B2 (ja) * | 2004-07-30 | 2010-07-21 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| US7588885B2 (en) * | 2004-08-06 | 2009-09-15 | Chung Yuan Christian University | Use of biocistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation |
| US20060068020A1 (en) * | 2004-09-24 | 2006-03-30 | Cottrell Ian W | Encapsulated pharmaceutical agents |
| JP4730584B2 (ja) | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| WO2006088010A1 (ja) * | 2005-02-15 | 2006-08-24 | Toagosei Co., Ltd. | 抗菌ペプチド及びその利用 |
| EP1940437B1 (de) | 2005-07-28 | 2013-09-04 | Biosynexus Incorporated | Zusammensetzungen und verfahren zur behandlung von bakterien |
| WO2008150845A1 (en) * | 2007-05-31 | 2008-12-11 | Vanderbilt University | Screening for wnt pathway modulators and pyrvinium for the treatment of cance |
| US9241908B2 (en) | 2007-10-16 | 2016-01-26 | Biocon Limited | Orally administrable solid pharmaceutical composition and a process thereof |
| EP2296685B1 (de) * | 2008-06-04 | 2015-09-02 | Synergy Pharmaceuticals Inc. | Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase |
| JP2011195451A (ja) * | 2008-06-20 | 2011-10-06 | Fukuoka Univ | ペプチド |
| US8773662B2 (en) * | 2010-07-22 | 2014-07-08 | Vuv Analytics, Inc. | Methods and apparatus for vacuum ultraviolet (VUV) or shorter wavelength circular dichroism spectroscopy |
| WO2012017215A1 (en) * | 2010-08-05 | 2012-02-09 | Helperby Therapeutics Limited | Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine |
| CN102167731B (zh) * | 2011-02-10 | 2013-01-23 | 周逸明 | 一种固相多肽合成奥米加南的制备方法 |
| US9487476B2 (en) | 2011-10-12 | 2016-11-08 | Yale University | Catechol diethers as potent anti-HIV agents |
| LT3030549T (lt) * | 2013-09-12 | 2019-06-25 | Janssen Biopharma, Inc. | Piridazinono junginiai ir jų panaudojimas |
| WO2015077057A1 (en) * | 2013-11-20 | 2015-05-28 | Texas Southern University | Methionine aminopeptidase inhibitors for treating infectious diseases |
| RU2678985C2 (ru) * | 2017-02-06 | 2019-02-05 | Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" | Биоцидный пептид и препарат на его основе |
| CN108721292B (zh) * | 2018-05-04 | 2022-04-01 | 中国疾病预防控制中心病毒病预防控制所 | 扑蛲灵在制备广谱抗冠状病毒药物中的应用 |
| WO2020252003A1 (en) | 2019-06-13 | 2020-12-17 | Hollister Incorporated | Reusable urinary catheter products |
| US12440644B2 (en) | 2019-06-25 | 2025-10-14 | Hollister Incorporated | Reusable urinary catheter products |
| KR102433665B1 (ko) * | 2021-11-17 | 2022-08-19 | 주식회사 씨위드 | 인돌리시딘 유래 항균 펩타이드 및 이의 용도 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2128617A (en) | 1982-10-06 | 1984-05-02 | Martti Vaara | Polypeptides for use in antibacterial therapy |
| NZ237202A (en) | 1990-02-23 | 1994-01-26 | Bristol Myers Squibb Co | Composition containing beta-lactam antibiotic and cationic oligopeptide |
| US5547939A (en) | 1991-06-14 | 1996-08-20 | The Regents Of The University Of California | Broad spectrum antimicrobial compounds and methods of use |
| US5324716A (en) | 1991-06-14 | 1994-06-28 | Regents Of The University Of California | Broad spectrum antimicrobial compounds and methods of use |
| US5593866A (en) | 1992-08-21 | 1997-01-14 | The University Of British Columbia | Cationic peptides and method for production |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| EP0759774B1 (de) | 1993-09-22 | 2002-06-12 | XOMA Technology Ltd. | Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum |
| DE69424680T2 (de) * | 1993-10-25 | 2000-09-28 | The Liposome Co.,Inc. | Liposomale defensine |
| WO1995019180A1 (en) | 1994-01-14 | 1995-07-20 | Xoma Corporation | Anti-gram-positive bacterial methods and materials |
| US5574017A (en) * | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
| US5877274A (en) | 1995-06-02 | 1999-03-02 | University Of British Columbia | Antimicrobial cationic peptides |
| AU6940796A (en) | 1995-08-23 | 1997-03-19 | University Of British Columbia, The | Antimicrobial cationic peptides and methods of screening for the same |
| US5994308A (en) | 1996-02-28 | 1999-11-30 | Board Of Trustees Of Southern Illinois University | Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use |
| US6180604B1 (en) * | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| US6551994B1 (en) | 1997-04-10 | 2003-04-22 | Mcgill University | Compounds and methods for inhibiting the interaction between α-catenin and β-catenin |
| WO1999043357A1 (en) | 1998-02-25 | 1999-09-02 | Micrologix Biotech Inc. | Indolicidin and cationic peptides conjugated with polymers |
-
1997
- 1997-08-20 US US08/915,314 patent/US6180604B1/en not_active Expired - Lifetime
- 1997-08-21 JP JP10510994A patent/JP2001500477A/ja active Pending
- 1997-08-21 DE DE69739035T patent/DE69739035D1/de not_active Expired - Lifetime
- 1997-08-21 ES ES97941352T patent/ES2178000T3/es not_active Expired - Lifetime
- 1997-08-21 WO PCT/US1997/014779 patent/WO1998007745A2/en not_active Ceased
- 1997-08-21 AT AT01119148T patent/ATE410441T1/de not_active IP Right Cessation
- 1997-08-21 DE DE69713112T patent/DE69713112T2/de not_active Expired - Lifetime
- 1997-08-21 ES ES01119148T patent/ES2315252T3/es not_active Expired - Lifetime
- 1997-08-21 EP EP97941352A patent/EP0925308B1/de not_active Expired - Lifetime
- 1997-08-21 AT AT97941352T patent/ATE218579T1/de active
- 1997-08-21 CA CA002263799A patent/CA2263799A1/en not_active Abandoned
-
2000
- 2000-09-22 US US09/667,486 patent/US6538106B1/en not_active Expired - Fee Related
-
2002
- 2002-07-08 HK HK02105059.5A patent/HK1043475B/en not_active IP Right Cessation
-
2003
- 2003-01-24 US US10/351,985 patent/US7390787B2/en not_active Expired - Fee Related
-
2004
- 2004-08-23 JP JP2004242925A patent/JP4073900B2/ja not_active Expired - Fee Related
-
2008
- 2008-03-28 US US12/058,500 patent/US20080242614A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2315252T3 (es) | 2009-04-01 |
| EP0925308A2 (de) | 1999-06-30 |
| DE69713112T2 (de) | 2003-01-30 |
| WO1998007745A2 (en) | 1998-02-26 |
| HK1043475B (en) | 2009-07-03 |
| EP0925308B1 (de) | 2002-06-05 |
| DE69739035D1 (de) | 2008-11-20 |
| JP2001500477A (ja) | 2001-01-16 |
| DE69713112D1 (de) | 2002-07-11 |
| ES2178000T3 (es) | 2002-12-16 |
| US7390787B2 (en) | 2008-06-24 |
| US6538106B1 (en) | 2003-03-25 |
| CA2263799A1 (en) | 1998-02-26 |
| US20040009910A1 (en) | 2004-01-15 |
| WO1998007745A3 (en) | 1998-07-09 |
| JP2005225857A (ja) | 2005-08-25 |
| HK1043475A1 (en) | 2002-09-13 |
| US6180604B1 (en) | 2001-01-30 |
| JP4073900B2 (ja) | 2008-04-09 |
| ATE410441T1 (de) | 2008-10-15 |
| US20080242614A1 (en) | 2008-10-02 |
| HK1021824A1 (en) | 2000-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE410441T1 (de) | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen | |
| ATE333464T1 (de) | Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika | |
| ES2563677T3 (es) | Composiciones de combinaciones de Neisseria | |
| DE69731373D1 (de) | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen | |
| ATE481480T1 (de) | Methoden und zusammensetzungen zur herstellung von polypeptiden | |
| MX9305729A (es) | Formulas de proteinas de liberacion sostenida. | |
| EP0720482A4 (de) | Prosaposin und von cytokin abgeleitete peptide als therapeutische wirkstoffe | |
| DE69823046D1 (de) | Praktische in vitro sialylierung von rekombinanten glykpproteinen | |
| NZ227788A (en) | Peptide having growth hormone regulatory effects, and compositions | |
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| DE60023860D1 (de) | Verfahren zur herstellung von rekombinanten peptiden | |
| DK0896615T3 (da) | Peptid fra opløselig form af acetylcholinesterase, der er aktivt som calcium-kanal-modulator | |
| ATE211391T1 (de) | Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung | |
| IL115381A0 (en) | Polypeptide compounds containing d-2-alkyltryptohan capable of promoting the release of growth hormone | |
| DE59712235D1 (de) | Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe | |
| EP1174439A3 (de) | Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen | |
| ATE385805T1 (de) | Neue peptide | |
| ATE390440T1 (de) | Neuroaktive peptide | |
| ATE405577T1 (de) | Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung | |
| ATE452903T1 (de) | Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten | |
| DE59108261D1 (de) | Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung | |
| DE69726602D1 (en) | Hepatitis b inhibitoren | |
| DE69534738D1 (de) | Leukocyten-aktivierender Faktor | |
| EA199801032A1 (ru) | Белки zona pellucida для контрацепции |